The role of CYP2D6 in the metabolism of antidepressants
¹ Medicine and Nutrition Faculty Juarez University of Durango State. Durango, Dgo., México, downton area.
² Genetic Department, Medicine and Nutrition Faculty, Juarez University of Durango State, Durango, Dgo., México.
Review Article
GSC Biological and Pharmaceutical Sciences, 2024, 27(03), 154–160.
Article DOI: 10.30574/gscbps.2024.27.3.0232
Publication history:
Received on 04 May 2024; revised on 15 June 2024; accepted on 18 June 2024
Abstract:
The cytochrome P450 2D6 plays an important role in the metabolism of several drugs, including antidepressants, and it also influences their efficacy and adverse effects. Some of the CYP2D6 genetic variants are closely related with a different metabolism way, depending on its type (PM, MI, normal, UM); that impacts mostly reducing the pharmacologic effects of drugs like haloperidol, duloxetine, venlafaxine, nortriptyline, paroxetine and others because their metabolism depends mainly from CYP2D6.
All of these reduced effects can impact negatively in the treatment of depression because they reduce its half-life elimination, and therefore also leads to reduce the acting time and maxim effect, which results in decreased therapeutic effect. Therefore, an alternative to improve the effectiveness of the treatment is to change it for an antidepressant which is not metabolized by CYP2D6.
Keywords:
CYP2D6; Genetic variant; Antidepressants; Depression; Metabolism; Ultra-rapid
Full text article in PDF:
Copyright information:
Copyright © 2024 Author(s) retain the copyright of this article. This article is published under the terms of the Creative Commons Attribution Liscense 4.0
